Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor
cells.
PURPOSE: Phase II trial to study the effectiveness of combining cetuximab with combination
chemotherapy in treating patients who have stage IV colorectal cancer.